Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

Rhea-AI Summary

Apogee Therapeutics (Nasdaq: APGE) will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis on May 27, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET, with a replay available afterward via its investor website.

News Market Reaction – APGE

-6.11%

8 alerts

-6.11% Session close to close

-33.9% Trough in 14 hr 23 min

$6.24B Market Cap

0.0x Rel. Volume

In the May 27 session, APGE declined 6.11%, reflecting a notable negative market reaction. Argus tracked a trough of -33.9% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.1% in the session following this news. A negative reaction despite this being onl...

Analysis

The stock moved -6.1% in the session following this news. A negative reaction despite this being only a scheduling announcement would fit a pattern where traders reassess risk ahead of binary clinical updates. Prior conference-call previews saw an average move of just 0.84%, so a sharp decline would likely reflect de-risking or profit-taking after a strong run above the 200-day moving average of $65.10. Thin pre-event volume of 262,991 versus a 640,161 average could also have magnified downside moves.

Key Figures

Part B duration: 16-week Trial phase: Phase 2 Results date: May 27, 2026 +1 more

4 metrics

Part B duration 16-week Phase 2 APEX Part B atopic dermatitis data window

Trial phase Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis

Results date May 27, 2026 Scheduled release of Part B 16-week APEX data

Conference time 8:00 a.m. ET Start time for webcast discussing Part B results

Previous Conferences,clinical trial Reports

3 past events · Latest: Mar 22 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 22	APEX Part A 52-week call	Neutral	+20.0%	Scheduled conference call to present Part A 52-week APEX results.
Jul 06	APEX Part A 16-week call	Neutral	-17.3%	Announcement of call to discuss Part A 16-week APEX data in AD.
Feb 28	APG990 interim results call	Neutral	-0.2%	Conference call set to review APG990 Phase 1 interim data and combo plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Conference-call clinical previews have produced mixed single-day moves, with an average reaction of 0.84% and no consistent directional pattern.

Recent Company History

This announcement fits a recurring pattern where Apogee schedules conference calls to preview clinical data for zumilokibart and other pipeline assets. Prior same-tag events on Feb 28, 2025, Jul 06, 2025, and Mar 22, 2026 highlighted interim Phase 1 results for APG990 and Phase 2 APEX Part A 16‑week and 52‑week data. Those notices were followed by detailed efficacy and safety updates in subsequent releases. Today’s Part B 16‑week readout call continues that staged disclosure approach within the APEX program.

Key Terms

phase 2, atopic dermatitis

2 terms

phase 2 medical

"report Part B 16-week data from the Phase 2 APEX trial of zumilokibart"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

atopic dermatitis medical

"APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Webcast to be held Wednesday, May 27th at 8:00 a.m. ET

SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details

Apogee Therapeutics’ live webcast of the Phase 2 APEX Part B results will begin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

About Apogee

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Noel.Kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com

FAQ

When will Apogee Therapeutics (APGE) report Part B 16-week Phase 2 APEX data?

Apogee Therapeutics will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026. According to Apogee, results will be discussed on a same-day conference call and webcast.

What time is Apogee Therapeutics' May 27, 2026 APEX trial webcast for APGE investors?

The webcast and conference call will begin at 8:00 a.m. ET on May 27, 2026. According to Apogee, investors can access the live event through its investor relations website.

How can investors access Apogee Therapeutics' Phase 2 APEX Part B results webcast?

Investors can access the live webcast via a provided link or through the Investors section of Apogee’s website. According to Apogee, a replay of the webcast will also be available after the call.

What trial data is Apogee Therapeutics (APGE) discussing on May 27, 2026?

Apogee Therapeutics will discuss Part B 16-week data from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. According to Apogee, these data will be presented during a webcast and conference call.

Will a replay of Apogee Therapeutics' May 27, 2026 APGE webcast be available?

Yes, a replay of the webcast will be available following the conference call. According to Apogee, investors can access this replay through the news and events section of its investor relations website.